| pubmed-article:15829494 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15829494 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:15829494 | lifeskim:mentions | umls-concept:C0679729 | lld:lifeskim |
| pubmed-article:15829494 | lifeskim:mentions | umls-concept:C0025202 | lld:lifeskim |
| pubmed-article:15829494 | lifeskim:mentions | umls-concept:C1518578 | lld:lifeskim |
| pubmed-article:15829494 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:15829494 | lifeskim:mentions | umls-concept:C0008838 | lld:lifeskim |
| pubmed-article:15829494 | lifeskim:mentions | umls-concept:C0076080 | lld:lifeskim |
| pubmed-article:15829494 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:15829494 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:15829494 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:15829494 | pubmed:dateCreated | 2005-5-23 | lld:pubmed |
| pubmed-article:15829494 | pubmed:abstractText | Temozolomide (TMZ) is an oral alkylating agent that produces methyl adducts at the 0.6 position of guanine. The methyl adducts are removed by the DNA repair enzyme AGAT. As demonstrated by in vitro studies, cisplatin (CDDP) is able to down-regulate the AGAT activity, suggesting that CDDP could enhance the antitumor activity of TMZ. We designed a randomized phase II study to evaluate and compare the activity and safety profile of the combination versus single-agent TMZ in patients with advanced melanoma. | lld:pubmed |
| pubmed-article:15829494 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15829494 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15829494 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15829494 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15829494 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15829494 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15829494 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15829494 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:15829494 | pubmed:issn | 0923-7534 | lld:pubmed |
| pubmed-article:15829494 | pubmed:author | pubmed-author:Christodoulou... | lld:pubmed |
| pubmed-article:15829494 | pubmed:author | pubmed-author:FountzilasGG | lld:pubmed |
| pubmed-article:15829494 | pubmed:author | pubmed-author:BafaloukosDD | lld:pubmed |
| pubmed-article:15829494 | pubmed:author | pubmed-author:BriassoulisEE | lld:pubmed |
| pubmed-article:15829494 | pubmed:author | pubmed-author:PolyzosAA | lld:pubmed |
| pubmed-article:15829494 | pubmed:author | pubmed-author:TsoutsosDD | lld:pubmed |
| pubmed-article:15829494 | pubmed:author | pubmed-author:KalofonosHH | lld:pubmed |
| pubmed-article:15829494 | pubmed:author | pubmed-author:EfstathiouEE | lld:pubmed |
| pubmed-article:15829494 | pubmed:author | pubmed-author:GogasHH | lld:pubmed |
| pubmed-article:15829494 | pubmed:author | pubmed-author:LinardouEE | lld:pubmed |
| pubmed-article:15829494 | pubmed:author | pubmed-author:KouroussisCC | lld:pubmed |
| pubmed-article:15829494 | pubmed:author | pubmed-author:PanagiotouPP | lld:pubmed |
| pubmed-article:15829494 | pubmed:author | pubmed-author:IconomouTT | lld:pubmed |
| pubmed-article:15829494 | pubmed:author | pubmed-author:ChalkidouSS | lld:pubmed |
| pubmed-article:15829494 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15829494 | pubmed:volume | 16 | lld:pubmed |
| pubmed-article:15829494 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15829494 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15829494 | pubmed:pagination | 950-7 | lld:pubmed |
| pubmed-article:15829494 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15829494 | pubmed:meshHeading | pubmed-meshheading:15829494... | lld:pubmed |
| pubmed-article:15829494 | pubmed:meshHeading | pubmed-meshheading:15829494... | lld:pubmed |
| pubmed-article:15829494 | pubmed:meshHeading | pubmed-meshheading:15829494... | lld:pubmed |
| pubmed-article:15829494 | pubmed:meshHeading | pubmed-meshheading:15829494... | lld:pubmed |
| pubmed-article:15829494 | pubmed:meshHeading | pubmed-meshheading:15829494... | lld:pubmed |
| pubmed-article:15829494 | pubmed:meshHeading | pubmed-meshheading:15829494... | lld:pubmed |
| pubmed-article:15829494 | pubmed:meshHeading | pubmed-meshheading:15829494... | lld:pubmed |
| pubmed-article:15829494 | pubmed:meshHeading | pubmed-meshheading:15829494... | lld:pubmed |
| pubmed-article:15829494 | pubmed:meshHeading | pubmed-meshheading:15829494... | lld:pubmed |
| pubmed-article:15829494 | pubmed:meshHeading | pubmed-meshheading:15829494... | lld:pubmed |
| pubmed-article:15829494 | pubmed:meshHeading | pubmed-meshheading:15829494... | lld:pubmed |
| pubmed-article:15829494 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15829494 | pubmed:articleTitle | Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group. | lld:pubmed |
| pubmed-article:15829494 | pubmed:affiliation | Department of Oncology, Metropolitan Hospital, Faliro, Greece. dimmp@otenet.gr | lld:pubmed |
| pubmed-article:15829494 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15829494 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:15829494 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:15829494 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:15829494 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15829494 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15829494 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15829494 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15829494 | lld:pubmed |
